ALXN

Alexion Pharmaceuticals, Inc. Press Releases

$161.44
*  
0.12
0.07%
Get ALXN Alerts
*Delayed - data as of Sep. 19, 2014  -  Find a broker to begin trading ALXN now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Alexion Strengthens and Broadens Its Executive Leadership Team
9/17/2014 7:30:00 AM - Business Wire

Improved Survival Observed in Pediatric Patients with Severe Hypophosphatasia (HPP) Who Were Treated with Investigational Asfotase Alfa for Up to Five Years
9/14/2014 5:30:00 PM - Business Wire

Asfotase Alfa Granted Orphan Drug Designation in Japan
9/8/2014 6:30:00 AM - Business Wire

NICE Recommends Commissioning of Eculizumab (Soliris®) for All Patients with aHUS in England
9/3/2014 7:01:00 PM - Business Wire

Alexion to Present at Investor Conferences
8/28/2014 10:00:00 AM - Business Wire

Alexion Initiates Multinational Registration Trial of Eculizumab for the Prevention of Delayed Graft Function (DGF) after Kidney Transplantation
8/25/2014 6:30:00 AM - Business Wire

Researchers to Present New Data on Asfotase Alfa in Pediatric Patients with Hypophosphatasia at the American Society for Bone and Mineral Research 2014 Annual Meeting
8/13/2014 4:57:00 PM - Business Wire

European Commission Grants Orphan Drug Designation to Soliris® (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)
8/1/2014 6:30:00 AM - Business Wire

Alexion Reports Second Quarter 2014 Results
7/24/2014 6:30:00 AM - Business Wire

European Medicines Agency Accepts Marketing Authorization Application for Asfotase Alfa as a Treatment for Patients with Hypophosphatasia
7/24/2014 6:15:00 AM - Business Wire

Alexion Announces the Appointments of David R. Brennan, M. Michele Burns and Christopher J. Coughlin to Its Board of Directors
7/16/2014 8:00:00 AM - Business Wire

Alexion Pharmaceuticals to Report Second Quarter 2014 Results on Thursday, July 24, 2014
7/10/2014 10:00:00 AM - Business Wire

Raptor Announces CEO Succession Plan; Dr. Christopher Starr to Retire as CEO at Year-end 2014, Julie Anne Smith Named President and CEO-Designate
7/7/2014 4:01:00 PM - GlobeNewswire

Biotech Equities under the Scanner -- Research on Alexion Pharma, InterMune, Cytokinetics, and Biogen Idec
7/7/2014 5:55:00 AM - PR Newswire

Alexion and Cincinnati Children's Launch Rare Disease Innovation Fund
6/23/2014 6:30:00 AM - PR Newswire

Alexion and Cincinnati Children’s Launch Rare Disease Innovation Fund
6/23/2014 6:30:00 AM - Business Wire